Pfizer (NYSE:PFE) recently presented groundbreaking findings in cancer research, particularly the first-in-human Phase 1 clinical study of the innovative MesoC2 drug at the ASCO Annual Meeting, and ...

Roche's Itovebi combo gains EMA panel endorsement for advanced breast cancer with PIK3CA mutation. Read more here.

Jim Cramer once confidently backed Pfizer, praising its pipeline and high dividend, forecasting a big post-COVID comeback. “I ...

President Trump threatens trade restrictions if foreign countries don't pay more for prescription drug costs. Read more here.